Novel Poly(ADP-ribose) Polymerase-1 Inhibitor, AG14361, Restores Sensitivity to Temozolomide in Mismatch Repair-Deficient Cells

Clinical Cancer Research

Volumn 10, Issue 3, 2004, Pages 881-889

  Curtin, Nicola J ^a   Wang, Lan Zhen ^a   Yiakouvaki, Anthie ^a   Kyle, Suzanne ^a   Arris, Christine A ^a   Canan Koch, Stacie ^b   Webber, Stephen E ^b   Durkacz, Barbara W ^a   Calvert, Hilary A ^a   Hostomsky, Zdenek ^b   Newell, David R ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 METHYLADENINE; 7 METHYLGUANINE; AG 14361; BENZYLGUANINE; CISPLATIN; DNA METHYLTRANSFERASE; DNA METHYLTRANSFERASE INHIBITOR; GUANINE DERIVATIVE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; TEMOZOLOMIDE; TOPOTECAN; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DNA METHYLATION; DNA STRAND BREAKAGE; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; DRUG RESISTANCE; DRUG SENSITIVITY; EXCISION REPAIR; GROWTH INHIBITION; HUMAN; HUMAN CELL; MISMATCH REPAIR; PRIORITY JOURNAL;

ADENINE; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; AZULENES; BASE PAIR MISMATCH; BENZODIAZEPINES; CELL DIVISION; CELL LINE, TUMOR; CISPLATIN; DACARBAZINE; DNA DAMAGE; DNA REPAIR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; ENZYME INHIBITORS; GENOTYPE; GUANINE; HUMANS; MODELS, CHEMICAL; NAD; POLY(ADP-RIBOSE) POLYMERASES;

EID: 10744233628     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-1144-3     Document Type: Article

References (43)

1. Friedman, H. S., Kerby, T., and Calvert, H. Temozolomide and the treatment of malignant glioma. Clin. Cancer Res., 6: 2585-2597, 2000.
2. Denny, B. J., Wheelhouse, R. T., Stevens, M. F. G., Tsang, L. L. H., and Slack, J. NMR and molecular modeling investigation of the mechanism of activation of the antitumour drug temozolomide and its interaction with DNA. Biochemistry, 33: 9045-9051, 1994.
3. 6-benzylguanine: a comparative study in vitro. Br. J. Cancer, 73: 482-490, 1996.
4. 6-benzylguanine and its role in chemotherapy. Clin. Cancer Res., 3: 837-847, 1997.
5. 6-benzylguanine potentiates the in vivo toxicity and clastogenicity of temozolomide and BCNU in mouse bone marrow. Blood, 89: 1566-1573, 1997.
6. 6-methylguanine-DNA methyltransferase in pretreatment tumour biopsies as a predictor of response to temozolomide in melanoma. Br. J. Cancer, 78: 1199-1202, 1998.
7. Liu, L., Markowitz, S., and Gerson SL, Mismatch repair mutations overide alkyltransferase in conferring resistance to temozolomide but not to 1, 3-bis(2-chloroethyl)nitrosourea. Cancer Res., 56: 5375-5379, 1996.
8. Friedman, H. S., McLendon, R. E., Kerby, T., Dugan, M., Bigner, S. H., Henry, A. J., Ashley, D. M., Krischer, J., Lovell, S., Rasheed, K., Marchev, F., Seman, A. J., Cokgor, I., Rich, J., Stewart, E., Colvin, O. M., Provenzale, J. M., Bigner, D. D., Haglund, M. M., Friedman, A. H., and Modrich, P. L. DNA mismatch repair and O-6-alkylguanine-DNA alkyltransferase analysis and response to temodal in newly diagnosed malignant glioma J. Clin. Oncol., 16: 3851-3857, 1998.
9. Modrich, P., and Lahue, R. Mismatch repair in replication fidelity, genetic recombination, and cancer biology. Annu. Rev. Biochem., 65: 101-133, 1996.
10. Herman, J. G., Uma, A., Polyak, K., Graff, J. R., Ahuja, N., Issa, J-P. J., Markowitz, S., Willson, J. K. V., Hamilton, S. R., Kinzler, K. W., Kane, M. F., Kolodner, R. D., Vogelstein, B., Kunkel, T. A., and Baylin, S. B. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc. Natl. Acad. Sci. USA, 95: 6870-6875, 1998.
11. Taverna, P., Liu, L., Hanson, A. J., Monks, A., and Gerson, S. L. Characterisation of MLH1 and MSH2 DA mismatch repair proteins in cell lines of the NCI anticancer drug screen. Cancer Chemother. Pharmacol., 46: 507-516, 2000.
12. Sedwick, W. D., Markowitz, S. D., and Veigl, M. Mismatch repair and drug responses in cancer. Drug Resistance Updates, 2: 295-306, 1999.
13. Tentori, L., Portarena, I., and Graziani, G. Potential clinical applications of poly(ADP-ribose) polymerase (PARP) inhibitors. Pharmacol. Rev., 45: 73-85, 2002.
14. Engelward, B. P., Allan, J. M., Dreslin, A. J., Kelly, J. D., Wu, M. M., Gold, B., and Samson, L. D. A chemical and genetic approach together define the biological consequences of 3-methyladenine lesions in the mammalian genome. J. Biol. Chem., 273: 5412-5418, 1998.
15. Hansen, W. K., and Kelley, M. R. Review of mammalian DNA repair and translational implications. J. Pharmacol. Exp. Ther., 295: 1-9, 2000.
16. Trucco, C., Oliver, F. J., deMurcia, G., and Menissier-de Murcia, J. DNA repair defect in poly(ADP-ribose) polymerase-deficient cell lines. Nucleic Acids Res., 26: 2644-2649, 1998.
17. Milam, K. M., Thomas, G. H., and Cleaver, J. E. Disturbances in DNA precursor metabolism associated with exposure to an inhibitor of poly(ADP-ribose) synthetase. Exp. Cell Res., 165: 260-268, 1986.
18. Moses, K., Willmore, E., Harris, A. L., and Durkacz, B. W. Correlation of enhanced 6-mercaptopurine cytotoxicity with increased phosphoribosylpyrophosphate levels in Chinese hamster ovary cells treated with 3-aminobenzamide. Cancer Res., 50: 1992-1996, 1990.
19. Skalitzky, D. J., Marakovits, J. T., Maegley, K. A., Ekker, A., Yu, X-H., Hostomsky, Z., Webber, S. E., Eastman, B. W., Almassy R. J., Li, J., Curtin, N. J., Newell, D. R., Calvert, A. H., Griffin, R. J., and Golding, B. T. Tricyclic benzimidazoles as potent PARP-1 inhibitors. J. Med. Chem., 46: 210-213, 2003.
20. Calabrese, C. R., Almassy, R., Barton, S., Batey, M. A., Calvert, A. H., Canan-Koch, S., Durkacz, B. W., Hostomsky, Z., Kumpf, R. A., Kyle, S., Li, J., Maegley, K., Newell, D. R., North, M., Notarianni, E., Stratford, I. J., Skalitzky, D., Thomas, H. D., Wang, L-Z., Webber, S. E., Williams, K. J., and Curtin, N. J. Preclinical evaluation of a novel poly(ADP-ribose) polymerase-1 (PARP-1) inhibitor, AG14361, with significant anticancer chemo- and radio-sensitization activity. J. Natl. Cancer Inst. (Bethesda), 96: 56-67, 2004.
21. Koi, M., Umar, A., Chauhan, D. P., Cherian, S. P., Carethers, J. M., Kunkel, T. A., and Boland, C. R. Human chromosome 3 corrects mismatch repair deficiency and microsatellite instability and reduces N-methyl-N′ -nitro-N-nitrosoguanidine tolerance in colon tumour cells with homozygous hMLH1 mutation. Cancer Res., 54: 4308-4312, 1994.
22. Delaney, C. A., Wang, L. Z., Kyle, S., Srinivasan, S., White, A. W., Calvert, A. H., Curtin, N. J., Durkacz, B. W., Hostomsky, Z., Maegley, K., Golding, B. T., Griffin, R. G., and Newell, D. R. Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines. Clin. Cancer Res., 6: 2860-2867, 2000.
23. Bowman, K. J., Newell, D. R., Calvert, A. H., and Curtin, N. J. Differential effects of the poly(ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity. Br. J. Cancer, 84: 106-112, 2001.
24. 6-methylguanine-DNA methyltransferase and comparison of detection methods for the methylated enzyme in polyacrylamide gels and electroblots. Biochem. J., 277: 89-96, 1991.
25. Behrens, B. C., Hamilton, T. C., Masuda, H., Grotzinger, K. R., Whang-Peng, J., Louie, K. G., Knutsen, T., McKoy, W. M., Young, R. C., and Ozols, R. F. Characterisation of a cis-diaminedichloroplatinum resistant human ovarian cell line and its use in the evaluation of platinum analogues. Cancer Res., 47: 414-418, 1987.
26. Brown, R., Hirst, G. H., Gallagher, W. M., Mcllwraith, A. J., Margison, G. P., Van der Dee, A. G., and Anthoney, D. A. HMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents. Oncogene, 15: 45-52, 1997.
27. Durant, S. T., Morris, M. M., Illand, M., McKay, H. J., McCormick, C., Hirst, G. L., Borts, R. H., and Brown, R. Dependence on RAD52 and RAD1 for anticancer drug resistance mediated by inactivation of mismatch repair genes. Curr. Biol., 9: 51-54, 1999.
28. Chen, T. R. In situ detection of mycoplasma contamination in cell cultures by fluorescent Hoechst 33258 stain. Exp. Cell Res., 104: 255-262, 1977.
29. Skehan, P., Storeng, R., Scudiero, D., Monks, A., McMahon, J., Vistica, D., Warren, J. T., Bokesch, H., Kenney, S., and Boyd, M. R. New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst. (Bethesda), 82: 1107-1112, 1990.
30. Kohn, K. W., Ewig, R. A., Erickson, L. C., and Zwelling, L. A. Measurement of strand breaks and cross-links by alkaline elution. In: E. C. Friberg and P. C. Hanawalt (eds), DNA Repair: A Laboratory Manual of Research Procedures, pp. 379-401. New York: Marcel Dekker, Inc., 1981.
31. Fornace, A. J., and Little, J. B. DNA crosslinking induced by X-rays and chemical agents. Biochim. Biophys. Acta, 477: 343-355, 1977.
32. Jacobson, E. L., and Jacobson, M. K. Tissue NAD as a biochemical measure of niacin status in humans. Methods Enzymol., 280: 221-230, 1997.
33. Anthoney, D. A., McIlwrath, A. J., Gallagher, W. M., Edlin, A. R. M., and Brown, R. Microsatellite instability, apoptosis and loss of p53 function in drug-resistant tumor cells. Cancer Res., 56: 1374-1381, 1996.
34. Lu, X-L., Errington, J., Curtin, N. J., Lunec, J., and Newell, D. R. The impact of p53 status on cellular sensitivity to antifolate drugs. Clin. Cancer Res., 7: 2114-2123, 2001.
35. Stevens, M. F. G., Hickman, J. A., Langdon, S. P., Chubb, D., Vickers, L., Stone, R., Baig, G., Goddard, C., Gibson, N. W., Slack, J. A., Newton, C., Lunt, E., Fizames, C., and Lavelle, F. Antitumour activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5, 1-d]-1, 2, 3, 5-tetrazin-4(3H)-one (CCRG 81045; M&B 39831), a novel drug with potential as an alternative to dacarbazine. Cancer Res., 47: 5846-5852, 1987.
36. Boulton, S., Pemberton, L. C., Porteous, J. K., Curtin, N. J., Griffin, R. J., Golding, B. T., and Durkacz, B. W. Potentiation of temozolomide cytotoxicity: a comparative study of the biological effects of poly(ADP-ribose) polymerase inhibitors. Br. J. Cancer, 72: 849-856, 1995.
37. Liu, L., Taverna, P., Whitacre, C. M., Chatterjee, S., and Gerson, S. L. Pharmacological disruption of base excision repair sensitizes mismatch repair-deficient and -proficient colon cancer cells to methylating agents. Clin. Cancer Res., 5: 2908-2917, 1999.
38. Tentori, L., Turriziani, M., Franco, D., Serafino, A., Levati, L., Roy, R., Bonmassar, E., and Graziani, G. Treatment with temozolomide and poly(ADP-ribose) polymerase inhibitors induces early apoptosis and increases base excision repair gene transcripts in leukaemic cells resistant to triazine compounds. Leukemia (Baltimore), 13: 901-909, 1999.
39. O'Connor, P. M., Jackman, J., Bae, I., Myers, T. G., Fan, S., Mutoh, M., Scudiero, D. A., Monks, A., Sausville, E. A., Weinstein, J. N., Friend, S., Fornace, A. J., and Kohn, K. W. Characterisation of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screed and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res., 57: 4285-4300, 1997.
40. Tentori, L., Vernole, P., Lacal, P. M., Madaio, R., Portarena, I., Levati, L., Balduzzi, A., Turriziani, M., Dande, P., Gold, B., Bonmassar, E., and Graziani, G. Cytotoxic and clastogenic effects of a DNA minor groove binding methyl sulfonate ester in mismatch repair deficient leukemic calls. Leukemia (Baltimore), 14: 1451-1459, 2000.
41. Mackay, H. J., Cameron, D., Rahilly, M., Mackean, M. J., Paul, J., Kaye, S. B., and Brown, R. Reduced MLH1 expression in breast tumours after primary chemotherapy predicts disease-free survival. J. Clin. Oncol., 18: 87-93, 2000.
42. Plumb, J. A., Strathdee, G., Sludden, J., Kaye, S. B., and Brown, R. Reversal of drug resistance in human tumour xenografts by 2′ -deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter. Cancer Res., 60: 6039-6044, 2000.
43. Moreland, N. J., Illand, M., Kim, T., Paul, J., and Brown, R. Modulation of drug resistance mediated by loss of mismatch repair by the DNA polymerase inhibitor aphidicolin. Cancer Res., 59: 2102-2106, 1999.